Savvy venture capitalists, biotech firms, and pharmaceutical companies have long recognized universities as technology troves of untapped value. In the last year or so, universities have developed a heightened perception of their own value--and are increasingly willing to exploit it through creative dealmaking. A look at the previous six months of licenses and research agreements signed between universities and pharmaceutical companies.
You may also be interested in...
Pharma’s opponents believe passage of the Inflation Reduction Act represents a momentum shift that will make it easier for politicians (even some Republicans) to take on the industry. They’ll need to count on that as they still have a long list of targets ahead on their lower-drug pricing agenda.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
The device giant is recalling Cobalt and Crome defibrillators because they may deliver weaker shocks than intended.